Tag: grants

SHREWSBURY, United Kingdom, July 15, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, the decentralized smart contract platform powered by artificial intelligence, has officially launched the Bonus Round of its presale following the successful completion of all 15 initial stages. With over $21 million raised from early supporters, the Bonus Round offers investors a final opportunity to participate at a fixed token price of $0.007.

CHICAGO, July 15, 2025 (GLOBE NEWSWIRE) -- Chicago Children’s Museum collaborated in a volunteer initiative alongside the SBB Research Group Foundation, which partners with local nonprofits through its Champion A Charity Program.   

VANCOUVER, British Columbia, July 12, 2025 (GLOBE NEWSWIRE) -- Canada-based and Solana-focused FinFra leader Astra Fintech today reinforced its commitment to the Solana ecosystem by announcing a $10M strategic acquisition of Dexlab, a pioneering Solana-native token launching and tooling platform. Backed by Astra’s recently launched $100 million Solana ecosystem fund, this deal marks a bold step in the company’s mission to accelerate PayFi adoption across Asia and beyond.

CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company’s board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.